106 related articles for article (PubMed ID: 10706091)
1. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
[TBL] [Abstract][Full Text] [Related]
2. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
3. Oral efficacy and bioavailability of a novel taxane.
Polizzi D; Pratesi G; Monestiroli S; Tortoreto M; Zunino F; Bombardelli E; Riva A; Morazzoni P; Colombo T; D'Incalci M; Zucchetti M
Clin Cancer Res; 2000 May; 6(5):2070-4. PubMed ID: 10815934
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of IDN5109 on head and neck squamous cell carcinoma.
Sano D; Matsuda H; Ishiguro Y; Nishimura G; Kawakami M; Tsukuda M
Oncol Rep; 2006 Feb; 15(2):329-34. PubMed ID: 16391850
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
6. Overcoming multidrug resistance in taxane chemotherapy.
Geney R; Ungureanu lM; Li D; Ojima I
Clin Chem Lab Med; 2002 Sep; 40(9):918-25. PubMed ID: 12435109
[TBL] [Abstract][Full Text] [Related]
7. Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
Ojima I; Geney R; Ungureanu IM; Li D
IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
[TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.
Colombo T; Frapolli R; Bombardelli E; Morazzoni P; Riva A; D'Incalci M; Zucchetti M
J Chromatogr B Biomed Sci Appl; 1999 Dec; 736(1-2):135-41. PubMed ID: 10676993
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic synergy from the taxane extract of Taxus chinensis improves the bioavailability of paclitaxel.
Liu Z; Zheng X; Lv J; Zhou X; Wang Q; Wen X; Liu H; Jiang J; Wang L
Phytomedicine; 2015 May; 22(5):573-8. PubMed ID: 25981924
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effects toward human hematopoietic progenitor cells and tumor cell lines of paclitaxel, docetaxel, and newly developed analogues IDN5109, IDN5111, and IDN5127.
Ferlini C; Distefano M; Pierelli L; Bonanno G; Riva A; Bombardelli E; Ojima I; Mancuso S; Scambia G
Oncol Res; 1999; 11(10):471-8. PubMed ID: 10850888
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
13. A novel taxane active against an orthotopically growing human glioma xenograft.
Laccabue D; Tortoreto M; Veneroni S; Perego P; Scanziani E; Zucchetti M; Zaffaroni M; D'Incalci M; Bombardelli E; Zunino F; Pratesi G
Cancer; 2001 Dec; 92(12):3085-92. PubMed ID: 11753988
[TBL] [Abstract][Full Text] [Related]
14. IDN 5390: an oral taxane candidate for protracted treatment schedules.
Pratesi G; Laccabue D; Lanzi C; Cassinelli G; Supino R; Zucchetti M; Frapolli R; D'Incalci M; Bombardelli E; Morazzoni P; Riva A; Zunino F
Br J Cancer; 2003 Mar; 88(6):965-72. PubMed ID: 12644838
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
17. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
18. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis.
Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C
Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942
[TBL] [Abstract][Full Text] [Related]
19. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
20. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
